Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se


Abdulkarim, K., Girodon, F., Johansson, P., Maynadie, M., Kutti, J., Carli, P. M., Andreasson, B. (2009). AML transformation in 56 patients with Ph- MPD in two well defined populations. European journal of haematology, 82(2), 106-111. doi:10.1111/j.1600-0609.2008.01163.x

Abelsson, J., Andreasson, B., Samuelsson, J., Hultcrantz, M., Ejerblad, E., Johansson, B., Johansson, P. (2013). Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma, 54(10), 2226-2230. doi:10.3109/10428194.2013.766732

Ahlstrand, E., Samuelsson, J., Lindgren, M., Pettersson, H., Liljeholm, M., Ravn-Landtblom, A., Andreasson, B. (2019). Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up. European journal of haematology. doi:10.1111/ejh.13373

Ahlstrand, E., Samuelsson, J., Lindgren, M., Pettersson, H., Liljeholm, M., Ravn-Landtblom, A., . Andreasson, B. (2020). Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up. European journal of haematology, 104(3), 271-278. doi:10.1111/ejh.13373

Al-Ali, H. K., Griesshammer, M., le Coutre, P., Waller, C. F., Liberati, A. M., Schafhausen, P., Vannucchi, A. M. (2016). Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica, 101(9), 1065-1073. doi:10.3324/haematol.2016.143677

Alimam, S., Bewley, S., Chappell, L. C., Knight, M., Seed, P., Gray, G., Robinson, S. (2016). Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol, 175(1), 31-36. doi:10.1111/bjh.14289

Alimam, S., Wilkins, B. S., & Harrison, C. N. (2015). How we diagnose and treat essential thrombocythaemia. Br J Haematol, 171(3), 306-321. doi:10.1111/bjh.13605

Alvarez-Larran, A., Cervantes, F., Pereira, A., Arellano-Rodrigo, E., Perez-Andreu, V., Hernandez-Boluda, J. C., Besses, C. (2010). Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood, 116(8), 1205-1210; quiz 1387. doi:10.1182/blood-2010-01-263319

Alvarez-Larran, A., Martinez-Aviles, L., Hernandez-Boluda, J. C., Ferrer-Marin, F., Antelo, M. L., Burgaleta, C., Besses, C. (2014). Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol, 93(12), 2037-2043. doi:10.1007/s00277-014-2152-7

Alvarez-Larran, A., Pereira, A., Arellano-Rodrigo, E., Hernandez-Boluda, J. C., Cervantes, F., & Besses, C. (2013). Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. Br J Haematol, 161(6), 865-871. doi:10.1111/bjh.12321

Alvarez-Larran, A., Pereira, A., Guglielmelli, P., Hernandez-Boluda, J. C., Arellano-Rodrigo, E., Ferrer-Marin, F., Besses, C. (2016). Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica, 101(8), 926-931. doi:10.3324/haematol.2016.146654

Anderson, L. A., Duncombe, A. S., Hughes, M., Mills, M. E., Wilson, J. C., & McMullin, M. F. (2012). Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol, 87(2), 175-182. doi:10.1002/ajh.22212

Andriani, A., Elli, E., Trape, G., Villiva, N., Fianchi, L., Di Veroli, A., Latagliata, R. (2019). Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. Hematol Oncol, 37(3), 291-295. doi:10.1002/hon.2635

Andriani, A., Montanaro, M., Voso, M. T., Villiva, N., Ciccone, F., Andrizzi, C., Latagliata, R. (2015). Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Leuk Res, 39(8), 801-804. doi:10.1016/j.leukres.2015.03.001

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-2405. doi:10.1182/blood-2016-03-643544

Badar, T., Kantarjian, H. M., Ravandi, F., Jabbour, E., Borthakur, G., Cortes, J. E., Verstovsek, S. (2015). Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res, 39(9), 950-956. doi:10.1016/j.leukres.2015.06.001

Bain, B. J. (2014). Blood cells [Elektronisk resurs] a practical guide. In. Chichester, West Sussex, United Kingdom: John Wiley & Sons.
Baldo, A., Sammarco, E., Plaitano, R., Martinelli, V., & Monfrecola. (2002). Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol, 147(5), 979-981. doi:10.1046/j.1365-2133.2002.04983.x

Baliakas, P., Tesi, B., Wartiovaara-Kautto, U., Stray-Pedersen, A. R., Friis, L. S., Dybedal, I., Andersen, M. K. (2019). Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up. Hemasphere, 3(6), e321. doi:10.1097/HS9.0000000000000321

Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Tefferi, A. (2011). Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol, 29(6), 761-770. doi:10.1200/jco.2010.31.8436

Barbui, T., De Stefano, V., Falanga, A., Finazzi, G., Martinelli, I., Rodeghiero, F., Barosi, G. (2019). Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. Blood Cancer J, 9(8), 61. doi:10.1038/s41408-019-0225-5

Barbui, T., & Finazzi, G. (2011). Special issues in myeloproliferative neoplasms. Curr Hematol Malig Rep, 6(1), 28-35. doi:10.1007/s11899-010-0073-7

Barbui, T., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Tefferi, A. (2012). Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood, 120(26), 5128-5133; quiz 5252. doi:10.1182/blood-2012-07-444067

Barbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Barosi, G. (2018). Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 32(5), 1057-1069. doi:10.1038/s41375-018-0077-1

Barbui, T., Thiele, J., Gisslinger, H., Finazzi, G., Carobbio, A., Rumi, E., Tefferi, A. (2014). Masked polycythemia vera (mPV): results of an international study. Am J Hematol, 89(1), 52-54. doi:10.1002/ajh.23585

Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Tefferi, A. (2011). Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol, 29(23), 3179-3184. doi:10.1200/jco.2010.34.5298

Barbui, T., Vannucchi, A. M., Buxhofer-Ausch, V., De Stefano, V., Betti, S., Rambaldi, A., Tefferi, A. (2015). Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J, 5, e369. doi:10.1038/bcj.2015.94

Barbui, T., Vannucchi, A. M., Carobbio, A., Rumi, E., Finazzi, G., Gisslinger, H., Tefferi, A. (2017). The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol, 92(1), E5-e6. doi:10.1002/ajh.24583

Barbui, T., Vannucchi, A. M., Finazzi, G., Finazzi, M. C., Masciulli, A., Carobbio, A., Tognoni, G. (2017). A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. Am J Hematol, 92(11), 1131-1136. doi:10.1002/ajh.24851

Barosi, G., Ambrosetti, A., Buratti, A., Finelli, C., Liberato, N. L., Quaglini, S., Ascari, E. (1993). Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia, 7(2), 200-206.

Barosi, G., Mesa, R., Finazzi, G., Harrison, C., Kiladjian, J. J., Lengfelder, E., Barbui, T. (2013). Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 121(23), 4778-4781. doi:10.1182/blood-2013-01-478891

Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., Schrag, D. (2016). Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol, 34(6), 557-565. doi:10.1200/jco.2015.63.0830

Bench, A. J., White, H. E., Foroni, L., Godfrey, A. L., Gerrard, G., Akiki, S., Cross, N. C. (2013). Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol, 160(1), 25-34. doi:10.1111/bjh.12075

Birgegard, G., Besses, C., Griesshammer, M., Gugliotta, L., Harrison, C. N., Hamdani, M., Kiladjian, J. J. (2018). Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica, 103(1), 51-60. doi:10.3324/haematol.2017.174672

Birgegard, G., Folkvaljon, F., Garmo, H., Holmberg, L., Besses, C., Griesshammer, M., Harrison, C. N. (2018). Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leuk Res, 74, 105-109. doi:10.1016/j.leukres.2018.10.006

Bjorkholm, M., Derolf, A. R., Hultcrantz, M., Kristinsson, S. Y., Ekstrand, C., Goldin, L. R., Landgren, O. (2011). Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol, 29(17), 2410-2415. doi:10.1200/jco.2011.34.7542

Boddu, P., Falchi, L., Hosing, C., Newberry, K., Bose, P., & Verstovsek, S. (2017). The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res, 58, 14-22. doi:10.1016/j.leukres.2017.03.008

Byun, J. M., Song, S., Koh, Y., Yoon, S. S., & Kim, D. (2019). The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms. Anticancer Res, 39(11), 6273-6282. doi:10.21873/anticanres.13837

Campbell, P. J., MacLean, C., Beer, P. A., Buck, G., Wheatley, K., Kiladjian, J. J., Green, A. R. (2012). Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood, 120(7), 1409-1411. doi:10.1182/blood-2012-04-424911

Carreau, N., Tremblay, D., Savona, M., Kremyanskaya, M., & Mascarenhas, J. (2016). Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. Blood Rev, 30(5), 349-356. doi:10.1016/j.blre.2016.04.003

Cervantes, F. (2014). How I treat myelofibrosis. Blood, 124(17), 2635-2642. doi:10.1182/blood-2014-07-575373

Cervantes, F., Alvarez-Larrán, A., Hernández-Boluda, J. C., Sureda, A., Torrebadell, M., & Montserrat, E. (2004). Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol, 127(4), 399-403. doi:10.1111/j.1365-2141.2004.05229.x

Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Tefferi, A. (2009). New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113(13), 2895-2901. doi:10.1182/blood-2008-07-170449

Cervantes, F., Hernández-Boluda, J. C., Alvarez, A., Nadal, E., & Montserrat, E. (2000). Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica, 85(6), 595-599.

Cervantes, F., Tassies, D., Salgado, C., Rovira, M., Pereira, A., & Rozman, C. (1991). Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol, 85(3), 124-127. doi:10.1159/000204873

Ciboddo, M., & Mullally, A. (2018). JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program, 2018(1), 110-117. doi:10.1182/asheducation-2018.1.110

Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995). Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med, 332(17), 1132-1136. doi:10.1056/nejm199504273321704
CPUP. Fatigue Severity Scale: CPUP. Uppföljningsprogram för cerabral pares. Retrieved from http://cpup.se/

Crisà, E., Cilloni, D., Elli, E. M., Martinelli, V., Palumbo, G. A., Pugliese, N., Ferrero, D. (2018). The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. Br J Haematol, 182(5), 701-704. doi:10.1111/bjh.15450

Curto-Garcia, N., Ianotto, J. C., & Harrison, C. N. (2018). What is pre-fibrotic myelofibrosis and how should it be managed in 2018? Br J Haematol, 183(1), 23-34. doi:10.1111/bjh.15562

De Gottardi, A., Trebicka, J., Klinger, C., Plessier, A., Seijo, S., Terziroli, B., Garcia-Pagan, J. C. (2017). Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int, 37(5), 694-699. doi:10.1111/liv.13285

De Stefano, V., Rossi, E., Carobbio, A., Ghirardi, A., Betti, S., Finazzi, G., Barbui, T. (2018). Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J, 8(11), 112. doi:10.1038/s41408-018-0151-y

De Stefano, V., Ruggeri, M., Cervantes, F., Alvarez-Larran, A., Iurlo, A., Randi, M. L., Barbui, T. (2016). High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia, 30(10), 2032-2038. doi:10.1038/leu.2016.85

De Stefano, V., Vannucchi, A. M., Ruggeri, M., Cervantes, F., Alvarez-Larran, A., Iurlo, A., Barbui, T. (2016). Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J, 6(11), e493. doi:10.1038/bcj.2016.103

De Stefano, V., Za, T., Rossi, E., Vannucchi, A. M., Ruggeri, M., Elli, E., Barbui, T. (2008). Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 93(3), 372-380. doi:10.3324/haematol.12053

Desterro, J., McLornan, D. P., Curto Garcia, N., O'Sullivan, J., Alimam, S., Keohane, C., Harrison, C. N. (2019). Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience. Br J Haematol, 186(4), 561-564. doi:10.1111/bjh.15968

DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000). Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med, 160(14), 2101-2107. doi:10.1001/archinte.160.14.2101

Douglas, G., Harrison, C., Forsyth, C., Bennett, M., Stevenson, W., Hounsell, J., Grigg, A. (2017). Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea. Leuk Lymphoma, 58(1), 89-95. doi:10.1080/10428194.2016.1187269

Duley, L., Meher, S., Hunter, K. E., Seidler, A. L., & Askie, L. M. (2019). Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev, 2019(10). doi:10.1002/14651858.CD004659.pub3

Eghtedar, A., Verstovsek, S., Estrov, Z., Burger, J., Cortes, J., Bivins, C., Ravandi, F. (2012). Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood, 119(20), 4614-4618. doi:10.1182/blood-2011-12-400051

Elliott, M. A., & Tefferi, A. (1999). Splenic irradiation in myelofibrosis with myeloid metaplasia: a review. Blood Rev, 13(3), 163-170. doi:10.1054/blre.1999.0110

ELN European Leukemia Net. Retrieved from https://www.leukemia-net.org/content/home/index_eng.html

Emanuel, R. M., Dueck, A. C., Geyer, H. L., Kiladjian, J. J., Slot, S., Zweegman, S., Mesa, R. A. (2012). Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol, 30(33), 4098-4103. doi:10.1200/jco.2012.42.3863

Enblom-Larsson, A., Girodon, F., Bak, M., Hersby, D., Jooste, V., Hasselbalch, H., Andreasson, B. (2017). A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera. Br J Haematol, 177(5), 800-805. doi:10.1111/bjh.14625

European Organization for Research on Treatment of Cancer (E O R T C). (1981). Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer, 44(1), 75-80. doi:10.1038/bjc.1981.150

Finazzi, G., Budde, U., & Michiels, J. J. (1996). Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Leuk Lymphoma, 22 Suppl 1, 71-78. doi:10.3109/10428199609074363

Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Barbui, T. (2012). Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia, 26(4), 716-719. doi:10.1038/leu.2011.258

Foldvari, M., & Bagonluri, M. (2008). Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties. Nanomedicine, 4(3), 173-182. doi:10.1016/j.nano.2008.04.002

Frederiksen, H., Szepligeti, S., Bak, M., Ghanima, W., Hasselbalch, H. C., & Christiansen, C. F. (2019). Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms - Impact Of Comorbidity. Clin Epidemiol, 11, 955-967. doi:10.2147/clep.S216787

Fruchtman, S. M., Mack, K., Kaplan, M. E., Peterson, P., Berk, P. D., & Wasserman, L. R. (1997). From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol, 34(1), 17-23.

Fu, R., Xuan, M., Lv, C., Zhang, L., Li, H., Zhang, X., Yang, R. (2014). External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients. European journal of haematology, 92(6), 502-509. doi:10.1111/ejh.12275

Gagelmann, N., Ditschkowski, M., Bogdanov, R., Bredin, S., Robin, M., Cassinat, B., Kroger, N. (2019). Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood, 133(20), 2233-2242. doi:10.1182/blood-2018-12-890889

Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Tefferi, A. (2011). DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol, 29(4), 392-397. doi:10.1200/jco.2010.32.2446

Gangat, N., Strand, J. J., Lasho, T. L., Li, C. Y., Pardanani, A., & Tefferi, A. (2008). Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol, 83(6), 451-453. doi:10.1002/ajh.21156

Gangat, N., Wolanskyj, A. P., Schwager, S., & Tefferi, A. (2009). Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. European journal of haematology, 82(5), 350-353. doi:10.1111/j.1600-0609.2009.01214.x

Gilbert, H. S. (1998). Familial myeloproliferative disease. Baillieres Clin Haematol, 11(4), 849-858. doi:10.1016/s0950-3536(98)80042-5

Gisslinger, H., Gotic, M., Holowiecki, J., Penka, M., Thiele, J., Kvasnicka, H. M., Petrides, P. E. (2013). Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood, 121(10), 1720-1728. doi:10.1182/blood-2012-07-443770

Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-Kyuchukova, L., Egyed, M., Kiladjian, J. J. (2020). Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol, 7(3), e196-e208. doi:10.1016/s2352-3026(19)30236-4

Godfrey, A. L., Campbell, P. J., MacLean, C., Buck, G., Cook, J., Temple, J., Harrison, C. N. (2018). Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. J Clin Oncol, Jco2018788414. doi:10.1200/jco.2018.78.8414

Gowin, K., Jain, T., Kosiorek, H., Tibes, R., Camoriano, J., Palmer, J., & Mesa, R. (2017). Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leuk Res, 54, 73-77. doi:10.1016/j.leukres.2017.01.006

Gowin, K., Thapaliya, P., Samuelson, J., Harrison, C., Radia, D., Andreasson, B., Mesa, R. (2012). Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica, 97(10), 1570-1573. doi:10.3324/haematol.2011.061390

Greer, I. A., & Nelson-Piercy, C. (2005). Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 106(2), 401-407. doi:10.1182/blood-2005-02-0626

Griesshammer, M. (2016). Outcomes in 121 pregnancies in patients with PV.

Griesshammer, M., Kiladjian, J. J., & Besses, C. (2019). Thromboembolic events in polycythemia vera. Ann Hematol, 98(5), 1071-1082. doi:10.1007/s00277-019-03625-x

Griesshammer, M., Sadjadian, P., & Wille, K. (2018). Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol, 11(9), 697-706. doi:10.1080/17474086.2018.1506325

Grinfeld, J., Nangalia, J., Baxter, E. J., Wedge, D. C., Angelopoulos, N., Cantrill, R., Campbell, P. J. (2018). Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med, 379(15), 1416-1430. doi:10.1056/NEJMoa1716614

Gupta, V., Kosiorek, H. E., Mead, A., Klisovic, R. B., Galvin, J. P., Berenzon, D., Hoffman, R. (2019). Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant, 25(2), 256-264. doi:10.1016/j.bbmt.2018.09.001

Haider, M., Gangat, N., Lasho, T., Abou Hussein, A. K., Elala, Y. C., Hanson, C., & Tefferi, A. (2016). Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol, 91(4), 390-394. doi:10.1002/ajh.24293

Harrison, C., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., Barosi, G. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med, 366(9), 787-798. doi:10.1056/NEJMoa1110556

Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Green, A. R. (2005). Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med, 353(1), 33-45. doi:10.1056/NEJMoa043800

Harrison, C. N., Mead, A. J., Panchal, A., Fox, S., Yap, C., Gbandi, E., McMullin, M. F. (2017). Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood, 130(17), 1889-1897. doi:10.1182/blood-2017-05-785790

Harrison, C. N., & Robinson, S. E. (2011). Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am, 25(2), 261-275, vii. doi:10.1016/j.hoc.2011.01.008

Harrison, C. N., Vannucchi, A. M., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Knoops, L., Barbui, T. (2016). Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia, 30(8), 1701-1707. doi:10.1038/leu.2016.148

Hasselbalch, H. C. (2011). A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol, 4(6), 637-655. doi:10.1586/ehm.11.63

Hernandez-Boluda, J. C., Arellano-Rodrigo, E., Cervantes, F., Alvarez-Larran, A., Gomez, M., Barba, P., Pereira, A. (2015). Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol, 94(6), 911-918. doi:10.1007/s00277-015-2330-2

Hernández-Boluda, J. C., Martínez-Trillos, A., García-Gutiérrez, V., Ferrer-Marín, F., Xicoy, B., Alvarez-Larrán, A., Cervantes, F. (2016). Long-term results of prednisone treatment for the anemia of myelofibrosis. Leuk Lymphoma, 57(1), 120-124. doi:10.3109/10428194.2015.1046866

Hoekstra, J., Bresser, E. L., Smalberg, J. H., Spaander, M. C., Leebeek, F. W., & Janssen, H. L. (2011). Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost, 9(11), 2208-2214. doi:10.1111/j.1538-7836.2011.04484.x

How, J., Trinkaus, K. M., & Oh, S. T. (2018). Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis. Br J Haematol, 183(2), 310-313. doi:10.1111/bjh.14958

Huang, B. T., Zeng, Q. C., Zhao, W. H., Li, B. S., & Chen, R. L. (2014). Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res, 38(10), 1177-1183. doi:10.1016/j.leukres.2014.06.019

Huang, J., & Tefferi, A. (2009). Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. European journal of haematology, 83(2), 154-155. doi:10.1111/j.1600-0609.2009.01266.x

Huang, M. S., Chen, Y. H., Wang, C. W., Yao, M., & Kuo, S. H. (2019). Low-dose splenic irradiation is an alternative therapy for symptomatic splenomegaly in patients with myelofibrosis. Ann Hematol, 98(4), 1037-1040. doi:10.1007/s00277-018-3461-z

Hulegardh, E., Nilsson, C., Lazarevic, V., Garelius, H., Antunovic, P., Rangert Derolf, A., Lehmann, S. (2015). Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol, 90(3), 208-214. doi:10.1002/ajh.23908

Hultcrantz, M., Bjorkholm, M., Dickman, P. W., Landgren, O., Derolf, A. R., Kristinsson, S. Y., & Andersson, T. M. L. (2018). Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study. Ann Intern Med, 168(5), 317-325. doi:10.7326/m17-0028

Hultcrantz, M., Kristinsson, S. Y., Andersson, T. M., Landgren, O., Eloranta, S., Derolf, A. R., Bjorkholm, M. (2012). Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol, 30(24), 2995-3001. doi:10.1200/jco.2012.42.1925

Hultcrantz, M., Ravn Landtblom, A., Andreasson, B., Samuelsson, J., Dickman, P. W., Kristinsson, S. Y., Andersson, T. M. (2020). Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden. J Intern Med. doi:10.1111/joim.13019

Ianotto, J. C., Couturier, M. A., Galinat, H., Mottier, D., Berthou, C., Guillerm, G., Delluc, A. (2017). Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol, 106(4), 517-521. doi:10.1007/s12185-017-2282-5

Ianotto, J. C., Kiladjian, J. J., Demory, J. L., Roy, L., Boyer, F., Rey, J., Abgrall, J. F. (2009). PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol, 146(2), 223-225. doi:10.1111/j.1365-2141.2009.07745.x

Interferon Alfa. (2006). In Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US).

Iwakawa, M., Noda, S., Yamada, S., Yamamoto, N., Miyazawa, Y., Yamazaki, H., Imai, T. (2006). Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer, 13(3), 300-307.

Jae, S. Y., Kurl, S., Laukkanen, J. A., Heffernan, K. S., Choo, J., Choi, Y. H., & Park, J. B. (2014). Higher blood hematocrit predicts hypertension in men. J Hypertens, 32(2), 245-250. doi:10.1097/hjh.0000000000000029

Jagsi, R., Chadha, M., Moni, J., Ballman, K., Laurie, F., Buchholz, T. A., Haffty, B. G. (2014). Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol, 32(32), 3600-3606. doi:10.1200/jco.2014.56.5838

Jayasuriya, N. A., Kjaergaard, A. D., Pedersen, K. M., Sorensen, A. L., Bak, M., Larsen, M. K., Ellervik, C. (2019). Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2.3 million people. Br J Haematol. doi:10.1111/bjh.16321

Johansson, P., Safai-Kutti, S., Lindstedt, G., Suurkula, M., & Kutti, J. (2002). Red cell mass, spleen size and plasma erythropoietin in polycythaemia vera and apparent polycythaemia. Acta Haematol, 108(1), 1-7. doi:10.1159/000063064

Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M., & Neugut, A. I. (2008). Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol, 26(3), 392-398. doi:10.1200/jco.2007.13.3033

Kennedy, J. A., Atenafu, E. G., Messner, H. A., Craddock, K. J., Brandwein, J. M., Lipton, J. H., Gupta, V. (2013). Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood, 121(14), 2725-2733. doi:10.1182/blood-2012-10-464248

Kiladjian, J. J., Chevret, S., Dosquet, C., Chomienne, C., & Rain, J. D. (2011). Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol, 29(29), 3907-3913. doi:10.1200/jco.2011.36.0792

Kiladjian, J. J., Chomienne, C., & Fenaux, P. (2008). Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia, 22(11), 1990-1998. doi:10.1038/leu.2008.280

Kristinsson, S. Y., Landgren, O., Samuelsson, J., Bjorkholm, M., & Goldin, L. R. (2010). Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica, 95(7), 1216-1220. doi:10.3324/haematol.2009.020412

Kroger, N. M., Deeg, J. H., Olavarria, E., Niederwieser, D., Bacigalupo, A., Barbui, T., Barosi, G. (2015). Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia, 29(11), 2126-2133. doi:10.1038/leu.2015.233

Kroll, M. E., Murphy, F., Pirie, K., Reeves, G. K., Green, J., & Beral, V. (2012). Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. Br J Cancer, 107(5), 879-887. doi:10.1038/bjc.2012.333

Landgren, O., Goldin, L. R., Kristinsson, S. Y., Helgadottir, E. A., Samuelsson, J., & Bjorkholm, M. (2008). Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood, 112(6), 2199-2204. doi:10.1182/blood-2008-03-143602

Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004). Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med, 350(2), 114-124. doi:10.1056/NEJMoa035572

Larsen, M. L., Pedersen, O. H., Hvas, A. M., Niekerk, P., Bonlokke, S., Kristensen, S. D., & Grove, E. L. (2019). Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. Platelets, 30(3), 322-328. doi:10.1080/09537104.2018.1430356

Lawless, S., McMullin, M. F., Cuthbert, R., & Houston, R. (2016). (32)P in the treatment of myeloproliferative disorders. Ulster Med J, 85(2), 83-85.

Le Gall-Ianotto, C., Brenaut, E., Gouillou, M., Lacut, K., Nowak, E., Tempescul, A., Ianotto, J. C. (2017). Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. Br J Dermatol, 176(1), 255-258. doi:10.1111/bjd.14809

Le Gall-Ianotto, C., Le Calloch, R., Couturier, M. A., Chauveau, A., Lippert, E., Carre, J. L., Ianotto, J. C. (2019). Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis. J Thromb Haemost, 17(11), 1950-1955. doi:10.1111/jth.14588

Lee, S. H., Erber, W. N., Porwit, A., Tomonaga, M., & Peterson, L. C. (2008). ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol, 30(5), 349-364. doi:10.1111/j.1751-553X.2008.01100.x

Lofvenberg, E., & Wahlin, A. (1988). Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. European journal of haematology, 41(4), 375-381. doi:10.1111/j.1600-0609.1988.tb00212.x

Macdonald, G., Kondor, N., Yousefi, V., Green, A., Wong, F., & Aquino-Parsons, C. (2004). Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol, 73(3), 367-371. doi:10.1016/j.radonc.2004.09.002

Malekzadeh, F., et al. (2005). Naturläkemedel och hormonpreparat - potentiell risk för bröstcancerpatienter. , 102.

Marchetti, M., Barosi, G., Balestri, F., Viarengo, G., Gentili, S., Barulli, S., Dupriez, B. (2004). Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol, 22(3), 424-431. doi:10.1200/JCO.2004.08.160

Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Barbui, T. (2005). Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol, 23(10), 2224-2232. doi:10.1200/jco.2005.07.062

Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., Barbui, T. (2013). Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med, 368(1), 22-33. doi:10.1056/NEJMoa1208500

Martinelli, I., De Stefano, V., Carobbio, A., Randi, M. L., Santarossa, C., Rambaldi, A., Barbui, T. (2014). Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study. Am J Hematol, 89(11), E200-205. doi:10.1002/ajh.23809

Martinez-Trillos, A., Gaya, A., Maffioli, M., Arellano-Rodrigo, E., Calvo, X., Diaz-Beya, M., & Cervantes, F. (2010). Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol, 89(12), 1233-1237. doi:10.1007/s00277-010-1019-9

Masarova, L., Bose, P., Newberry, K., Abou Zahr, A., Cortes, J. E., Kantarjian, H. M., & Verstovsek, S. (2017). Correlation between blast percentage in myelofibrosis and outcomes: A single-center experience. Journal of Clinical Oncology, 35(15_suppl), e18562-e18562. doi:10.1200/JCO.2017.35.15_suppl.e18562

Mascarenhas, J., Navada, S., Malone, A., Rodriguez, A., Najfeld, V., & Hoffman, R. (2010). Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res, 34(9), 1246-1249. doi:10.1016/j.leukres.2010.05.008

Maze, D., Kazi, S., Gupta, V., Malinowski, A. K., Fazelzad, R., Shah, P. S., & Shehata, N. (2019). Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis. JAMA Netw Open, 2(10), e1912666. doi:10.1001/jamanetworkopen.2019.12666

McLornan, D., Szydlo, R., Koster, L., Chalandon, Y., Robin, M., Wolschke, C., Yakoub-Agha, I. (2019). Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 25(11), 2167-2171. doi:10.1016/j.bbmt.2019.06.034

McLornan, D. P., Yakoub-Agha, I., Robin, M., Chalandon, Y., Harrison, C. N., & Kroger, N. (2019). State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica, 104(4), 659-668. doi:10.3324/haematol.2018.206151

McMullin, M. F., Harrison, C. N., Ali, S., Cargo, C., Chen, F., Ewing, J., Mead, A. J. (2019). A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol, 184(2), 176-191. doi:10.1111/bjh.15648

McMullin, M. F. F., Mead, A. J., Ali, S., Cargo, C., Chen, F., Ewing, J., Harrison, C. N. (2019). A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline. Br J Haematol, 184(2), 161-175. doi:10.1111/bjh.15647

Menage, H. D., Norris, P. G., Hawk, J. L., & Graves, M. W. (1993). The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. Br J Dermatol, 129(2), 163-165. doi:10.1111/j.1365-2133.1993.tb03520.x

Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., Sundar, H. (2017). NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw, 15(10), 1193-1207. doi:10.6004/jnccn.2017.0157

Mesa, R. A., Li, C. Y., Ketterling, R. P., Schroeder, G. S., Knudson, R. A., & Tefferi, A. (2005). Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood, 105(3), 973-977. doi:10.1182/blood-2004-07-2864

Mesa, R. A., Nagorney, D. S., Schwager, S., Allred, J., & Tefferi, A. (2006). Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer, 107(2), 361-370. doi:10.1002/cncr.22021

Mesa, R. A., Steensma, D. P., Pardanani, A., Li, C. Y., Elliott, M., Kaufmann, S. H., Tefferi, A. (2003). A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 101(7), 2534-2541. doi:10.1182/blood-2002-09-2928

Mesa, R. A., Yao, X., Cripe, L. D., Li, C. Y., Litzow, M., Paietta, E., Tallman, M. S. (2010). Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood, 116(22), 4436-4438. doi:10.1182/blood-2010-05-287417

Michiels, J. J., Berneman, Z. N., Schroyens, W., & Van Vliet, H. H. (2004). Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets, 15(2), 67-84. doi:10.1080/09537100310001646969

Mondello, P., Di Mirto, C., Cuzzocrea, S., Arrigo, C., Mian, M., & Pitini, V. (2019). Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk, 19(8), e489-e495. doi:10.1016/j.clml.2019.03.027

Murphy, F., Kroll, M. E., Pirie, K., Reeves, G., Green, J., & Beral, V. (2013). Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer, 108(11), 2390-2398. doi:10.1038/bjc.2013.159

Mwirigi, A., Galli, S., Keohane, C., Raj, K., Radia, D. H., Harrison, C. N., & McLornan, D. P. (2014). Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol, 167(5), 714-716. doi:10.1111/bjh.13046

Naymagon, L., & Mascarenhas, J. (2017). Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies. Hemasphere, 1(1), e1. doi:10.1097/HS9.0000000000000001

Nielsen, I., & Hasselbalch, H. C. (2003). Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol, 74(1), 26-31. doi:10.1002/ajh.10375

Nilsson, C., Hulegardh, E., Garelius, H., Mollgard, L., Brune, M., Wahlin, A., Lehmann, S. (2019). Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. Biol Blood Marrow Transplant, 25(9), 1770-1778. doi:10.1016/j.bbmt.2019.05.038

Nilsson, C., Hulegårdh, E., Garelius, H., Möllgård, L., Brune, M., Wahlin, A., Lehmann, S. (2019). Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. Biol Blood Marrow Transplant, 25(9), 1770-1778. doi:10.1016/j.bbmt.2019.05.038

Noor, S. J., Tan, W., Wilding, G. E., Ford, L. A., Barcos, M., Sait, S. N., Wetzler, M. (2011). Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. Leuk Res, 35(5), 608-613. doi:10.1016/j.leukres.2010.07.031

O'Neill, C., Siddiqi, I., Brynes, R. K., Vergara-Lluri, M., Moschiano, E., & O'Connell, C. (2016). Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. Ann Hematol, 95(5), 733-738. doi:10.1007/s00277-016-2631-0

Pardanani, A., Lasho, T. L., Finke, C. M., Mai, M., McClure, R. F., & Tefferi, A. (2010). IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia, 24(6), 1146-1151. doi:10.1038/leu.2010.77

Pascale, S., Petrucci, G., Dragani, A., Habib, A., Zaccardi, F., Pagliaccia, F., Patrono, C. (2012). Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood, 119(15), 3595-3603. doi:10.1182/blood-2011-06-359224

Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Tefferi, A. (2010). A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115(9), 1703-1708. doi:10.1182/blood-2009-09-245837

Passamonti, F., Giorgino, T., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Vannucchi, A. M. (2017). A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 31(12), 2726-2731. doi:10.1038/leu.2017.169

Passamonti, F., Mora, B., Giorgino, T., Guglielmelli, P., Cazzola, M., Maffioli, M., Vannucchi, A. M. (2017). Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia, 31(4), 970-973. doi:10.1038/leu.2016.351

Passamonti, F., Randi, M. L., Rumi, E., Pungolino, E., Elena, C., Pietra, D., Lazzarino, M. (2007). Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood, 110(2), 485-489. doi:10.1182/blood-2007-01-071068

Passamonti, F., Rumi, E., Arcaini, L., Castagnola, C., Lunghi, M., Bernasconi, P., Lazzarino, M. (2005). Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer, 104(5), 1032-1036. doi:10.1002/cncr.21297

Passamonti, F., Thiele, J., Girodon, F., Rumi, E., Carobbio, A., Gisslinger, H., Tefferi, A. (2012). A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood, 120(6), 1197-1201. doi:10.1182/blood-2012-01-403279

Peginterferon Alfa. (2006). In Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US).

Peterson, C. (2005). Naturläkemedel - egenvård på egen risk! Fara för okända biverkningar och interaktioner med "vanliga" läkemedel. . Läkartidningen, 102.

Pettersson, H., Anderson, L., Abelsson, J., Samuelsson, J., Johansson, P., Duncombe, A., Andréasson, B. Newly Diagnosed Patients with Polycythemia Vera and Essential Thrombocythemia Have an Impaired Quality of Life Compared to Age-Matched Control Individuals. 6(7).

Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Binno, S. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J, 37(29), 2315-2381. doi:10.1093/eurheartj/ehw106

Pietra, D., Rumi, E., Ferretti, V. V., Di Buduo, C. A., Milanesi, C., Cavalloni, C., Cazzola, M. (2016). Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia, 30(2), 431-438. doi:10.1038/leu.2015.277

Pizzi, M., Silver, R. T., Barel, A., & Orazi, A. (2015). Recombinant interferon-alpha in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol, 28(10), 1315-1323. doi:10.1038/modpathol.2015.93

Podoltsev, N. A., Wang, X., Wang, R., Hofmann, J. N., Liao, L. M., Zeidan, A. M., Ma, X. (2020). Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study. Int J Cancer. doi:10.1002/ijc.32853

Prochazka, M., Granath, F., Ekbom, A., Shields, P. G., & Hall, P. (2002). Lung cancer risks in women with previous breast cancer. Eur J Cancer, 38(11), 1520-1525.

Quintas-Cardama, A., Abdel-Wahab, O., Manshouri, T., Kilpivaara, O., Cortes, J., Roupie, A. L., Verstovsek, S. (2013). Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood, 122(6), 893-901. doi:10.1182/blood-2012-07-442012

Quintas-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., Verstovsek, S. (2009). Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol, 27(32), 5418-5424. doi:10.1200/jco.2009.23.6075

Quintas-Cardama, A., Kantarjian, H. M., Manshouri, T., Thomas, D., Cortes, J., Ravandi, F.,  Verstovsek, S. (2009). Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol, 27(28), 4760-4766. doi:10.1200/JCO.2009.22.6548

Robinson, S. E., & Harrison, C. N. (2020). How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy. Br J Haematol, 189(4), 625-634. doi:10.1111/bjh.16453

Rocca, B., Tosetto, A., Betti, S., Soldati, D., Petrucci, G., Rossi, E.,  De Stefano, V. (2020). A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood, 136(2), 171-182. doi:10.1182/blood.2019004596

Rumi, E., Boveri, E., Bellini, M., Pietra, D., Ferretti, V. V., Sant'Antonio, E., Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative, I. (2017). Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget, 8(60), 101735-101744. doi:10.18632/oncotarget.21594

Rumi, E., & Cazzola, M. (2017). Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood, 129(6), 680-692. doi:10.1182/blood-2016-10-695957

Rungjirajittranon, T., Owattanapanich, W., Ungprasert, P., Siritanaratkul, N., & Ruchutrakool, T. (2019). A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer, 19(1), 184. doi:10.1186/s12885-019-5387-9

Saini, K. S., Patnaik, M. M., & Tefferi, A. (2010). Polycythemia vera-associated pruritus and its management. Eur J Clin Invest, 40(9), 828-834. doi:10.1111/j.1365-2362.2010.02334.x

Santos, F. P., Tam, C. S., Kantarjian, H., Cortes, J., Thomas, D., Pollock, R., & Verstovsek, S. (2014). Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma, 55(1), 121-127. doi:10.3109/10428194.2013.794269

Scherber, R. M., Kosiorek, H. E., Senyak, Z., Dueck, A. C., Clark, M. M., Boxer, M. A., Mesa, R. A. (2016). Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer, 122(3), 477-485. doi:10.1002/cncr.29753

Shanavas, M., Popat, U., Michaelis, L. C., Fauble, V., McLornan, D., Klisovic, R., Gupta, V. (2016). Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant, 22(3), 432-440. doi:10.1016/j.bbmt.2015.10.005

Sharp, L., Johansson, H., Hatschek, T., & Bergenmar, M. (2013). Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast, 22(5), 634-638. doi:10.1016/j.breast.2013.07.047

Shaw, G., & Berg, R. (2019). Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera. Clin Med Res. doi:10.3121/cmr.2019.1483

Siegel, F. P., Tauscher, J., & Petrides, P. E. (2013). Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol, 88(8), 665-669. doi:10.1002/ajh.23474

Silver, R., Krichevsky, S., Gjoni, S., & Cross, N. (2017). Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera. Leuk Lymphoma, 58, 1-2. doi:10.1080/10428194.2017.1300892

Silver, R. T., Vandris, K., & Goldman, J. J. (2011). Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood, 117(24), 6669-6672. doi:10.1182/blood-2010-11-320069

Skeith, L., Carrier, M., Robinson, S. E., Alimam, S., & Rodger, M. A. (2017). Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. Blood, 129(8), 934-939. doi:10.1182/blood-2016-09-728006

Smalberg, J. H., Arends, L. R., Valla, D. C., Kiladjian, J. J., Janssen, H. L., & Leebeek, F. W. (2012). Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood, 120(25), 4921-4928. doi:10.1182/blood-2011-09-376517

Spivak, J. L. (2002). The optimal management of polycythaemia vera. Br J Haematol, 116(2), 243-254. doi:10.1046/j.1365-2141.2002.03287.x

Spivak, J. L. (2017). Myeloproliferative Neoplasms. N Engl J Med, 376(22), 2168-2181. doi:10.1056/NEJMra1406186

Tait, C., Baglin, T., Watson, H., Laffan, M., Makris, M., Perry, D., & Keeling, D. (2012). Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol, 159(1), 28-38. doi:10.1111/j.1365-2141.2012.09249.x

Tam, C. S., Nussenzveig, R. M., Popat, U., Bueso-Ramos, C. E., Thomas, D. A., Cortes, J. A., Verstovsek, S. (2008). The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood, 112(5), 1628-1637. doi:10.1182/blood-2008-02-138230

Tefferi, A. (2014). Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol, 89(9), 915-925. doi:10.1002/ajh.23703

Tefferi, A. (2018). Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol, 93(12), 1551-1560. doi:10.1002/ajh.25230

Tefferi, A., & Fonseca, R. (2002). Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood, 99(7), 2627. doi:10.1182/blood.v99.7.2627

Tefferi, A., Guglielmelli, P., Lasho, T. L., Rotunno, G., Finke, C., Mannarelli, C., Vannucchi, A. M. (2014). CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia, 28(7), 1494-1500. doi:10.1038/leu.2014.57

Tefferi, A., Guglielmelli, P., Nicolosi, M., Mannelli, F., Mudireddy, M., Bartalucci, N., Vannucchi, A. M. (2018). GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 32(7), 1631-1642. doi:10.1038/s41375-018-0107-z

Tefferi, A., Lasho, T. L., Finke, C. M., Elala, Y., Hanson, C. A., Ketterling, R. P., Pardanani, A. (2016). Targeted deep sequencing in primary myelofibrosis. Blood Adv, 1(2), 105-111. doi:10.1182/bloodadvances.2016000208

Tefferi, A., Lasho, T. L., Guglielmelli, P., Finke, C. M., Rotunno, G., Elala, Y., Vannucchi, A. M. (2016). Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv, 1(1), 21-30. doi:10.1182/bloodadvances.2016000216

Tefferi, A., Mesa, R. A., Nagorney, D. M., Schroeder, G., & Silverstein, M. N. (2000). Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood, 95(7), 2226-2233.

Tefferi, A., Mudireddy, M., Mannelli, F., Begna, K. H., Patnaik, M. M., Hanson, C. A., Vannucchi, A. M. (2018). Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia, 32(5), 1200-1210. doi:10.1038/s41375-018-0019-y

Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Barbui, T. (2013). Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 27(9), 1874-1881. doi:10.1038/leu.2013.163

Teofili, L., Valentini, C. G., Rossi, E., & De Stefano, V. (2019). Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis? Leukemia, 33(1), 279-281. doi:10.1038/s41375-018-0304-9

Terasako, K., & Sasai, S. (1998). Platelet transfusion for surgery in the presence of polycythemia vera. Acta Anaesthesiol Scand, 42(2), 270-271. doi:10.1111/j.1399-6576.1998.tb05122.x

Thepot, S., Itzykson, R., Seegers, V., Raffoux, E., Quesnel, B., Chait, Y., Ades, L. (2010). Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood, 116(19), 3735-3742. doi:10.1182/blood-2010-03-274811

Twomey, R., Martin, T., Temesi, J., Culos-Reed, S. N., & Millet, G. Y. (2018). Tailored exercise interventions to reduce fatigue in cancer survivors: study protocol of a randomized controlled trial. BMC Cancer, 18(1), 757. doi:10.1186/s12885-018-4668-z

van Genderen, P. J., Mulder, P. G., Waleboer, M., van de Moesdijk, D., & Michiels, J. J. (1997). Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol, 97(1), 179-184. doi:10.1046/j.1365-2141.1997.d01-2127.x

Vannucchi, A. M., Barbui, T., Cervantes, F., Harrison, C., Kiladjian, J. J., Kroger, N., Buske, C. (2015). Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 26 Suppl 5, v85-99. doi:10.1093/annonc/mdv203

Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Verstovsek, S. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med, 372(5), 426-435. doi:10.1056/NEJMoa1409002

Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Tefferi, A. (2013). Mutations and prognosis in primary myelofibrosis. Leukemia, 27(9), 1861-1869. doi:10.1038/leu.2013.119

Ware, R. E., Marahatta, A., Ware, J. L., McElhinney, K., Dong, M., & Vinks, A. A. (2020). Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). J Pediatr. doi:10.1016/j.jpeds.2020.02.002

Wells, M., Macmillan, M., Raab, G., MacBride, S., Bell, N., MacKinnon, K., Munro, A. (2004). Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol, 73(2), 153-162. doi:10.1016/j.radonc.2004.07.032

Verstovsek, S., Gotlib, J., Mesa, R. A., Vannucchi, A. M., Kiladjian, J. J., Cervantes, F., Gupta, V. (2017). Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol, 10(1), 156. doi:10.1186/s13045-017-0527-7

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Kantarjian, H. M. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 366(9), 799-807. doi:10.1056/NEJMoa1110557

Wille, K., Sadjadian, P., Becker, T., Kolatzki, V., Horstmann, A., Fuchs, C., & Griesshammer, M. (2019). High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Ann Hematol, 98(1), 93-100. doi:10.1007/s00277-018-3483-6

Wu, M., Schuster, M., & Tadros, M. (2019). Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants. J Clin Transl Hepatol, 7(2), 154-164. doi:10.14218/jcth.2018.00057

Zaorsky, N. G., Williams, G. R., Barta, S. K., Esnaola, N. F., Kropf, P. L., Hayes, S. B., & Meyer, J. E. (2017). Splenic irradiation for splenomegaly: A systematic review. Cancer Treat Rev, 53, 47-52. doi:10.1016/j.ctrv.2016.11.016

Nästa kapitel
21 Förslag på fördjupning